Mustang Bio Inc. (MBIO)
MBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001680048 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $14.3M cash; operating cash flow -$1.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 7,584,078 (2026-11-03); 7,299,086 a year earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2025-01-16 | Source 2025-01-16 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-17 |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $237, sold $241 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$964K | -$876K | $14.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$1.1M | -$967K | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | Not filed | -$955K | -$1.0M | $16.3M | No debt tags | Needs four quarters | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | Not filed | -$538K | -$1.7M | $17.3M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$468K | -$818K | $19.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$762K | -$1.3M | $12.7M | No debt tags | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | Not filed | -$153K | -$1.4M | $14.2M | No debt tags | Needs four quarters | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | Not filed | -$952K | -$2.0M | $6.8M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-09-05 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-10-15 |
| Latest proxy | DEF 14A | 2025-12-03 |
Source: SEC EDGAR submissions feed, 405 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.6% |
| 1 month | +11.7% |
| 3 months | -29.1% |
| Year to date | -57.1% |
| 1 year | -65.2% |
| From 52-week high | -70.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier